McKesson Pays $190mil for Claims of Defrauding the Medicaid Reimbursement Program
Posted Apr 30 2012 9:00am
McKesson, the largest US drug distributor, agreed to pay more than $190 million to resolve claims that it caused the U.S. to overpay for prescription drugs. As Bloomberg News reports , a New Jersey lawsuit claimed McKesson defrauded the Medicaid Program by falsely reporting inflated prices of drugs, which in turn caused the federal government to set higher reimbursement rates. Under the agreement, state governments can separately negotiate with McKesson, meaning more fines could be on the way.
This story isn’t new. Every year companies are fined millions of dollars for a variety of offenses, both large and small. At the 17th annual Medicaid Drug Rebate Program Summit , September 10-12, in Chicago, we do everything possible to give you the information you need to avoid audits and be compliant, to ensure the next story in the news cycle isn’t about your company’s million dollar fine. We have more CMS, OPA, OIG, and DoJ officials, as well as industry legal heads to explain who is getting caught, why, and how to avoid those actionable behaviors.
Register today to attend the nation’s longest running and most respected event in the MDRP space!